Video+

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations.

Joaquim Bellmunt outlines the latest analysis from the JAVELIN Bladder 100 trial pointing to a potential role for chromatin conformation loops as a biomarker of maintenance avelumab benefit in advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Toni Choueiri tells us about the COSMIC-313 trial evaluating the addition of cabozantinib to nivolumab plus ipilimumab in intermediate- or poor-risk patients with treatment-naïve, advanced renal cell carcinoma.

Enrique Grande Pulido takes us through an exploratory analysis of the IMvigor130 trial of atezolizumab in metastatic urothelial cancer focusing on the differences in outcomes according to the assay used to assess PD-L1 expression, and highlights the clinical relevance of the findings.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

Tian Zhang shares her top picks from the genitourinary cancers tracks at the 2022 ASCO Annual Meeting, including the EVEREST trial and updates from TheraP and EV-301.

Andrea Apolo and Elizabeth Plimack discuss highlights of the ASCO 22 Annual Meeting. Here, they talk about some of the exciting new data presented on the use of antibody-drug conjugates targeting HER2, which are starting to show promise for the treatment of urothelial carcinoma (UC). 

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Harold Burstein takes us through the breast cancer studies that caught his attention at the 2022 ASCO Annual Meeting, including the DESTINY-Breast04 and LUMINA trials.

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved.

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC. 

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a RET fusion

Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps.

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions.